1
|
Di Maida F, Grosso AA, Cadenar A, Gallo ML, Giudici S, Paganelli D, Olivera L, Mari A, Masieri L, Minervini A. Step-by-step robotic technique to manage an extensive retroperitoneal fibrosis. Cent European J Urol 2023; 76:347-348. [PMID: 38230316 PMCID: PMC10789281 DOI: 10.5173/ceju.2023.193] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2023] [Revised: 08/18/2023] [Accepted: 09/12/2023] [Indexed: 01/18/2024] Open
Affiliation(s)
- Fabrizio Di Maida
- Department of Experimental and Clinical Medicine, University of Florence, Unit of Oncologic Minimally Invasive Urology and Andrology, Careggi Hospital, Florence, Italy
| | - Antonio Andrea Grosso
- Department of Experimental and Clinical Medicine, University of Florence, Unit of Oncologic Minimally Invasive Urology and Andrology, Careggi Hospital, Florence, Italy
| | - Anna Cadenar
- Department of Experimental and Clinical Medicine, University of Florence, Unit of Oncologic Minimally Invasive Urology and Andrology, Careggi Hospital, Florence, Italy
| | - Maria Lucia Gallo
- Department of Experimental and Clinical Medicine, University of Florence, Unit of Oncologic Minimally Invasive Urology and Andrology, Careggi Hospital, Florence, Italy
| | - Sofia Giudici
- Department of Experimental and Clinical Medicine, University of Florence, Unit of Oncologic Minimally Invasive Urology and Andrology, Careggi Hospital, Florence, Italy
| | - Daniele Paganelli
- Department of Experimental and Clinical Medicine, University of Florence, Unit of Oncologic Minimally Invasive Urology and Andrology, Careggi Hospital, Florence, Italy
| | - Laura Olivera
- Department of Experimental and Clinical Medicine, University of Florence, Unit of Oncologic Minimally Invasive Urology and Andrology, Careggi Hospital, Florence, Italy
| | - Andrea Mari
- Department of Experimental and Clinical Medicine, University of Florence, Unit of Oncologic Minimally Invasive Urology and Andrology, Careggi Hospital, Florence, Italy
| | - Lorenzo Masieri
- Department of Experimental and Clinical Medicine, University of Florence, Unit of Oncologic Minimally Invasive Urology and Andrology, Careggi Hospital, Florence, Italy
| | - Andrea Minervini
- Department of Experimental and Clinical Medicine, University of Florence, Unit of Oncologic Minimally Invasive Urology and Andrology, Careggi Hospital, Florence, Italy
| |
Collapse
|
2
|
Maida FD, Cadenar A, Grosso AA, Lambertini L, Giudici S, Paganelli D, Salamone V, Mari A, Salvi M, Minervini A, Tuccio A. Predictors of early catheter replacement after HoLEP. Results from a high-volume laser center. Int Braz J Urol 2023; 49:608-618. [PMID: 37506034 PMCID: PMC10482466 DOI: 10.1590/s1677-5538.ibju.2023.0165] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2023] [Accepted: 07/07/2023] [Indexed: 07/30/2023] Open
Abstract
INTRODUCTION The aim of the study was to investigate clinical and surgical factors associated with early catheter replacement in patients treated with Holmium Laser Enucleation of the Prostate (HoLEP). MATERIALS AND METHODS Data of patients treated with HoLEP at our Institution by a single surgeon from March 2017 to January 2021 were collected. Preoperative variables, including non-invasive uroflowmetry and abdominal ultrasonography (US), were recorded. Bladder wall modifications (BWM) at preoperative US were defined as the presence of single or multiple bladder diverticula or bladder wall thickening 5 mm. Clinical symptoms were assessed using validated questionnaires. Only events occurred within the first week after catheter removal were considered. RESULTS Overall, 305 patients were included, of which 46 (15.1%) experienced early catheter replacement. Maintenance of anticoagulants/antiplatelets (AC/AP) therapy at surgery (p=0.001), indwelling urinary catheter (p=0.02) and the presence of BWM (p=0.001) were more frequently reported in patients needing postoperative re-catheterization. Intraoperative complications (p=0.02) and median lasing time (p=0.02) were significantly higher in this group. At univariate analysis, indwelling urinary catheter (p=0.02), BWM (p=0.01), ongoing AC/AP therapy (p=0.01) and intraoperative complications (p=0.01) were significantly associated with early catheter replacement. At multivariate analysis, indwelling urinary catheter (OR: 1.28; p=0.02), BWM (OR: 2.87; p=0.001), and AC/AP therapy (OR: 2.21; p=0.01) were confirmed as independent predictors of catheter replacement. CONCLUSIONS In our experience the presence of indwelling urinary catheter before surgery, BWM and the maintenance of AC/AP therapy were shown to be independent predictors of early catheter replacement after HoLEP.
Collapse
Affiliation(s)
- Fabrizio Di Maida
- University of FlorenceUnit of Oncologic Minimally Invasive Urology and AndrologyDepartment of Experimental and Clinical MedicineFlorenceItalyDepartment of Experimental and Clinical Medicine, University of Florence - Unit of Oncologic Minimally Invasive Urology and Andrology, Careggi Hospital, Florence, Italy
| | - Anna Cadenar
- University of FlorenceUnit of Oncologic Minimally Invasive Urology and AndrologyDepartment of Experimental and Clinical MedicineFlorenceItalyDepartment of Experimental and Clinical Medicine, University of Florence - Unit of Oncologic Minimally Invasive Urology and Andrology, Careggi Hospital, Florence, Italy
| | - Antonio Andrea Grosso
- University of FlorenceUnit of Oncologic Minimally Invasive Urology and AndrologyDepartment of Experimental and Clinical MedicineFlorenceItalyDepartment of Experimental and Clinical Medicine, University of Florence - Unit of Oncologic Minimally Invasive Urology and Andrology, Careggi Hospital, Florence, Italy
| | - Luca Lambertini
- University of FlorenceUnit of Oncologic Minimally Invasive Urology and AndrologyDepartment of Experimental and Clinical MedicineFlorenceItalyDepartment of Experimental and Clinical Medicine, University of Florence - Unit of Oncologic Minimally Invasive Urology and Andrology, Careggi Hospital, Florence, Italy
| | - Sofia Giudici
- University of FlorenceUnit of Oncologic Minimally Invasive Urology and AndrologyDepartment of Experimental and Clinical MedicineFlorenceItalyDepartment of Experimental and Clinical Medicine, University of Florence - Unit of Oncologic Minimally Invasive Urology and Andrology, Careggi Hospital, Florence, Italy
| | - Daniele Paganelli
- University of FlorenceUnit of Oncologic Minimally Invasive Urology and AndrologyDepartment of Experimental and Clinical MedicineFlorenceItalyDepartment of Experimental and Clinical Medicine, University of Florence - Unit of Oncologic Minimally Invasive Urology and Andrology, Careggi Hospital, Florence, Italy
| | - Vincenzo Salamone
- University of FlorenceUnit of Oncologic Minimally Invasive Urology and AndrologyDepartment of Experimental and Clinical MedicineFlorenceItalyDepartment of Experimental and Clinical Medicine, University of Florence - Unit of Oncologic Minimally Invasive Urology and Andrology, Careggi Hospital, Florence, Italy
| | - Andrea Mari
- University of FlorenceUnit of Oncologic Minimally Invasive Urology and AndrologyDepartment of Experimental and Clinical MedicineFlorenceItalyDepartment of Experimental and Clinical Medicine, University of Florence - Unit of Oncologic Minimally Invasive Urology and Andrology, Careggi Hospital, Florence, Italy
| | - Matteo Salvi
- University of FlorenceUnit of Oncologic Minimally Invasive Urology and AndrologyDepartment of Experimental and Clinical MedicineFlorenceItalyDepartment of Experimental and Clinical Medicine, University of Florence - Unit of Oncologic Minimally Invasive Urology and Andrology, Careggi Hospital, Florence, Italy
| | - Andrea Minervini
- University of FlorenceUnit of Oncologic Minimally Invasive Urology and AndrologyDepartment of Experimental and Clinical MedicineFlorenceItalyDepartment of Experimental and Clinical Medicine, University of Florence - Unit of Oncologic Minimally Invasive Urology and Andrology, Careggi Hospital, Florence, Italy
| | - Agostino Tuccio
- University of FlorenceUnit of Oncologic Minimally Invasive Urology and AndrologyDepartment of Experimental and Clinical MedicineFlorenceItalyDepartment of Experimental and Clinical Medicine, University of Florence - Unit of Oncologic Minimally Invasive Urology and Andrology, Careggi Hospital, Florence, Italy
| |
Collapse
|
3
|
Di Maida F, Grosso AA, Tellini R, Nardoni S, Giudici S, Cadenar A, Salamone V, Lambertini L, Salvi M, Minervini A, Tuccio A. Holmium laser enucleation of the prostate (HoLEP) is safe and effective in patients with high comorbidity burden. Int Braz J Urol 2023; 49:341-350. [PMID: 36794848 DOI: 10.1590/s1677-5538.ibju.2022.0174] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2022] [Accepted: 02/06/2023] [Indexed: 02/17/2023] Open
Abstract
INTRODUCTION We assessed the efficacy and safety of holmium laser enucleation of the prostate (HoLEP) in patients with high comorbidity burden. MATERIALS AND METHODS Data from patients treated with HoLEP at our academic referral center from March 2017 to January 2021 were prospectively collected. Patients were divided according to their CCI (Charlson Comorbidity Index). Perioperative surgical data and 3-month functional outcomes were collected. RESULTS Out of 305 patients included, 107 (35.1%) and 198 (64.9%) were classified as CCI ≥ 3 and < 3, respectively. The groups were comparable in terms of baseline prostate size, symptoms severity, post-void residue and Qmax. The amount of energy delivered during HoLEP (141.3 vs. 118.0 KJ, p=0.01) and lasing time (38 vs 31 minutes, p=0.01) were significantly higher in patients with CCI ≥ 3. However, median enucleation, morcellation and overall surgical time were comparable between the two groups (all p>0.05). Intraoperative complications rate (9.3% vs. 9.5%, p=0.77), median time to catheter removal and hospital stay were comparable between the two cohorts. Similarly, early (30 days) and delayed (>30 days) surgical complications rates were not significantly different between the two groups. At 3-month follow up, functional outcomes using validated questionnaires did not differ between the two groups (all p>0.05). CONCLUSIONS HoLEP represents a safe and effective treatment option for BPH also in patients with high comorbidity burden.
Collapse
Affiliation(s)
- Fabrizio Di Maida
- Department of Experimental and Clinical Medicine, University of Florence - Unit of Oncologic Minimally Invasive Urology and Andrology, Careggi Hospital, Florence, Italy
| | - Antonio Andrea Grosso
- Department of Experimental and Clinical Medicine, University of Florence - Unit of Oncologic Minimally Invasive Urology and Andrology, Careggi Hospital, Florence, Italy
| | - Riccardo Tellini
- Department of Experimental and Clinical Medicine, University of Florence - Unit of Oncologic Minimally Invasive Urology and Andrology, Careggi Hospital, Florence, Italy
| | - Samuele Nardoni
- Department of Experimental and Clinical Medicine, University of Florence - Unit of Oncologic Minimally Invasive Urology and Andrology, Careggi Hospital, Florence, Italy
| | - Sofia Giudici
- Department of Experimental and Clinical Medicine, University of Florence - Unit of Oncologic Minimally Invasive Urology and Andrology, Careggi Hospital, Florence, Italy
| | - Anna Cadenar
- Department of Experimental and Clinical Medicine, University of Florence - Unit of Oncologic Minimally Invasive Urology and Andrology, Careggi Hospital, Florence, Italy
| | - Vincenzo Salamone
- Department of Experimental and Clinical Medicine, University of Florence - Unit of Oncologic Minimally Invasive Urology and Andrology, Careggi Hospital, Florence, Italy
| | - Luca Lambertini
- Department of Experimental and Clinical Medicine, University of Florence - Unit of Oncologic Minimally Invasive Urology and Andrology, Careggi Hospital, Florence, Italy
| | - Matteo Salvi
- Department of Experimental and Clinical Medicine, University of Florence - Unit of Oncologic Minimally Invasive Urology and Andrology, Careggi Hospital, Florence, Italy
| | - Andrea Minervini
- Department of Experimental and Clinical Medicine, University of Florence - Unit of Oncologic Minimally Invasive Urology and Andrology, Careggi Hospital, Florence, Italy
| | - Agostino Tuccio
- Department of Experimental and Clinical Medicine, University of Florence - Unit of Oncologic Minimally Invasive Urology and Andrology, Careggi Hospital, Florence, Italy
| |
Collapse
|
4
|
Mari A, Giudici S, Tellini R, Lambertini L, Di Maida F, Amparore D, Antonelli A, Bacchiani M, Porpiglia F, Schiavina R, Brunocilla E, Capitanio U, Da Pozzo L, Fiori C, Gontero P, Longo N, Montorsi F, Simeone C, Serni S, Siracusano S, Ficarra V, Minervini A. Laparoscopic versus robot-assisted partial nephrectomy for cT1 renal tumors in obese patients: Analysis of perioperative and follow-up functional outcomes (the RECORd2 project). Eur Urol 2023. [DOI: 10.1016/s0302-2838(23)01055-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
5
|
Grosso AA, Di Maida F, Nardoni S, Salvi M, Giudici S, Lambertini L, Cadenar A, Tellini R, Cocci A, Mari A, Minervini A, Tuccio A. Patterns and Predictors of Optimal Surgical and Functional Outcomes after Holmium Laser Enucleation of the Prostate (HoLEP): Introducing the Concept of "Trifecta". World J Mens Health 2023:41.e6. [PMID: 36593708 DOI: 10.5534/wjmh.220042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2022] [Revised: 05/23/2022] [Accepted: 06/07/2022] [Indexed: 01/03/2023] Open
Abstract
PURPOSE The present study sought to provide reproducible and patient-oriented metrics to assess the rate of "successful" outcomes (Trifecta) following holmium laser enucleation of the prostate (HoLEP). Clinical and surgical predictors of failure to achieve Trifecta were investigated. MATERIALS AND METHODS We queried our prospectively collected database of all patients treated with HoLEP between March 2017 and January 2021. Trifecta was defined as the contemporary presence of: (1) no postoperative complication within 3 months; (2) no urinary incontinence at 3-months follow-up; and (3) 3-month postoperative max flow-rate >15 mL/s. Cases were grouped according to Trifecta achievement. All surgical procedures were carried out by a single surgeon. Surgical experience was divided into two different eras according to the number of procedures conducted (surgical era). Multivariate logistic regression analysis was performed to assess predictors of Trifecta failure. RESULTS Overall 305 patients were included. Of these, 192 patients (63.0%) achieved Trifecta. Preoperative patient-related features were comparable between the two groups, except for a higher post-void residual (PVR) in non-Trifecta patients (median 180 vs. 130 mL, p=0.003). A significant proportion of Trifecta patients (88.5%) were treated in the second surgical era and in 126 (65.6%) cases an en-bloc enucleation was performed. Multivariate analysis confirmed PVR ≥250 mL, first surgical era and standard three-lobes enucleation technique as independent predictors of Trifecta failure. CONCLUSIONS In our experience the rate of "successful" HoLEP, defined according to our newly introduced Trifecta metric, was 63.0%. We demonstrated that surgical strategy together with rising experience and baseline PVR are key elements to forecast the outcomes.
Collapse
Affiliation(s)
- Antonio Andrea Grosso
- Department of Experimental and Clinical Medicine, University of Florence - Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy
| | - Fabrizio Di Maida
- Department of Experimental and Clinical Medicine, University of Florence - Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy
| | - Samuele Nardoni
- Department of Experimental and Clinical Medicine, University of Florence - Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy
| | - Matteo Salvi
- Department of Experimental and Clinical Medicine, University of Florence - Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy
| | - Sofia Giudici
- Department of Experimental and Clinical Medicine, University of Florence - Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy
| | - Luca Lambertini
- Department of Experimental and Clinical Medicine, University of Florence - Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy
| | - Anna Cadenar
- Department of Experimental and Clinical Medicine, University of Florence - Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy
| | - Riccardo Tellini
- Department of Experimental and Clinical Medicine, University of Florence - Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy
| | - Andrea Cocci
- Department of Experimental and Clinical Medicine, University of Florence - Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy
| | - Andrea Mari
- Department of Experimental and Clinical Medicine, University of Florence - Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy
| | - Andrea Minervini
- Department of Experimental and Clinical Medicine, University of Florence - Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy
| | - Agostino Tuccio
- Department of Experimental and Clinical Medicine, University of Florence - Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy.
| |
Collapse
|
6
|
Di Maida F, Campi R, Grosso AA, Lambertini L, Cadenar A, Giudici S, Pecoraro A, Mari A, Serni S, Minervini A, Belmonte M, Catucci C, Mariottini R, Marzocco A, Moscardi L, Livio V, Mazzola L. Prognostic features of upstaged pT3a renal tumors with fat invasion after robot-assisted partial nephrectomy: is it time for a new subclassification? European Journal of Surgical Oncology 2022; 49:862-867. [PMID: 36528511 DOI: 10.1016/j.ejso.2022.11.098] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2022] [Revised: 11/06/2022] [Accepted: 11/19/2022] [Indexed: 11/27/2022]
Abstract
INTRODUCTION The clinical management of pT3a pathologic-upstaged renal cell carcinoma (RCC) patients is actually controversial. Aim of this study was i) to assess the impact of pT3a upstaging on oncologic outcomes after robot-assisted partial nephrectomy (RAPN) for cT1-T2 RCC; ii) to explore clinical and surgical predictors of pT3a upstaging; iii) to evaluate the differential impact of perinephric fat invasion (PFI) or sinus fat invasion (SFI) on survival outcomes after RAPN in case of upstaged pT3a RCC. MATERIALS AND METHODS Clinical and surgical data from consecutive RCCs treated with RAPN in a single referral centre between January 2017 and June 2021 were prospectively collected and retrospectively reviewed. Pathological upstaging to pT3a tumors with fat invasion was further stratified in SFI or PFI. Uni- and multivariable analysis were fitted to explore clinical and surgical predictors of disease recurrence. RESULTS Overall, 1852 patients were enrolled and 179 (9.7%) with pT3a upstaging were found. Median age was 65 (IQR 56-73) years with a median BMI of 25.6 (23.6-29.0). At a median follow up of 26 (9-38) months, 76 (4.1%) patients showed disease recurrence. Multivariable analysis confirmed PADUA score ≥10 (OR 1.76, CI 95% 1.18-1.91, p = 0.001), age at surgery (OR 1.04, CI 95% 1.01-1.06, p = 0.01), clinical tumor diameter (OR 1.31, CI 95% 1.17-1.47, p = 0.001), tumor necrosis (OR 1.54, CI 95% 1.08-1.88, p = 0.001) and nucleolar grading ≥3 (OR 1.27, CI 95% 1.01-1.44, p = 0.001) as independent predictors of pT3a upstaging. Multivariate Cox regression model showed pathological sinus fat invasion as an independent predictor of disease recurrence (HR 3.43, CI 95% 1.51-7.77, p = 0.003) in pT3a upstaged group. CONCLUSION In pathologically upstaged pT3a RCCs, sinus fat invasion was confirmed as independent predictor of disease relapse. In this light, the definition of novel risk categories in the pT3a patients setting should be encouraged.
Collapse
|
7
|
Lambertini L, Di Maida F, Grosso A, Cadenar A, Nardoni S, Giudici S, Valastro F, Vannuccini S, Capezzuoli T, Fambrini M, Petraglia F, Mari A, Minervini A. Urinary tract endometriosis: how to predict and prevent recurrence after primary surgical excision. EUR UROL SUPPL 2022. [DOI: 10.1016/s2666-1683(22)01103-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
|
8
|
Grosso AA, Di Maida F, Giudici S, Mari A, Muiesan P, Taddei A, Campi R, Minervini A. Robotic surgery for renal tumors with inferior vena cava thrombosis: Indications and technical nuances. Urology Video Journal 2022. [DOI: 10.1016/j.urolvj.2021.100111] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
9
|
Di Maida F, Mari A, Grosso A, Lambertini L, Valastro F, Bisegna C, Giudici S, Cangemi V, Viola L, Tellini R, Fantechi R, Vittori G, Masieri L, Carini M, Minervini A. Robot assisted radical cystectomy with florence robotic intracorporeal neobladder (FloRIN): analysis of survival and functional outcomes after first 100 consecutive patients upon accomplishment of phase 3 ideal framework. EUR UROL SUPPL 2021. [DOI: 10.1016/s2666-1683(21)00857-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
10
|
Aliberti R, Ambrosino F, Ammendola R, Angelucci B, Antonelli A, Anzivino G, Arcidiacono R, Bache T, Baeva A, Baigarashev D, Barbanera M, Bernhard J, Biagioni A, Bician L, Biino C, Bizzeti A, Blazek T, Bloch-Devaux B, Bonaiuto V, Boretto M, Bragadireanu AM, Britton D, Brizioli F, Brunetti MB, Bryman D, Bucci F, Capussela T, Carmignani J, Ceccucci A, Cenci P, Cerny V, Cerri C, Checcucci B, Conovaloff A, Cooper P, Cortina Gil E, Corvino M, Costantini F, Cotta Ramusino A, Coward D, D'Agostini G, Dainton JB, Dalpiaz P, Danielsson H, De Simone N, Di Filippo D, Di Lella L, Doble N, Duk V, Duval F, Döbrich B, Emelyanov D, Engelfried J, Enik T, Estrada-Tristan N, Falaleev V, Fantechi R, Fascianelli V, Federici L, Fedotov S, Filippi A, Fiorini M, Fry JR, Fu J, Fucci A, Fulton L, Gamberini E, Gatignon L, Georgiev G, Ghinescu SA, Gianoli A, Giorgi M, Giudici S, Gonnella F, Goudzovski E, Graham C, Guida R, Gushchin E, Hahn F, Heath H, Henshaw J, Holzer EB, Husek T, Hutanu OE, Hutchcroft D, Iacobuzio L, Iacopini E, Imbergamo E, Jenninger B, Jerhot J, Jones RWL, Kampf K, Kekelidze V, Kholodenko S, Khoriauli G, Khotyantsev A, Kleimenova A, Korotkova A, Koval M, Kozhuharov V, Kucerova Z, Kudenko Y, Kunze J, Kurochka V, Kurshetsov V, Lamanna G, Lanfranchi G, Lari E, Latino G, Laycock P, Lazzeroni C, Lehmann Miotto G, Lenti M, Leonardi E, Lichard P, Litov L, Lollini R, Lomidze D, Lonardo A, Lubrano P, Lupi M, Lurkin N, Madigozhin D, Mannelli I, Mapelli A, Marchetto F, Marchevski R, Martellotti S, Massarotti P, Massri K, Maurice E, Medvedeva M, Mefodev A, Menichetti E, Migliore E, Minucci E, Mirra M, Misheva M, Molokanova N, Moulson M, Movchan S, Napolitano M, Neri I, Newson F, Norton A, Noy M, Numao T, Obraztsov V, Ostankov A, Padolski S, Page R, Palladino V, Parenti A, Parkinson C, Pedreschi E, Pepe M, Perrin-Terrin M, Peruzzo L, Petrov P, Petrov Y, Petrucci F, Piandani R, Piccini M, Pinzino J, Polenkevich I, Pontisso L, Potrebenikov Y, Protopopescu D, Raggi M, Romano A, Rubin P, Ruggiero G, Ryjov V, Salamon A, Santoni C, Saracino G, Sargeni F, Schuchmann S, Semenov V, Sergi A, Shaikhiev A, Shkarovskiy S, Soldi D, Sozzi M, Spadaro T, Spinella F, Sturgess A, Sugonyaev V, Swallow J, Trilov S, Valente P, Velghe B, Venditti S, Vicini P, Volpe R, Vormstein M, Wahl H, Wanke R, Wrona B, Yushchenko O, Zamkovsky M, Zinchenko A. Search for Lepton Number and Flavor Violation in K^{+} and π^{0} Decays. Phys Rev Lett 2021; 127:131802. [PMID: 34623867 DOI: 10.1103/physrevlett.127.131802] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/17/2021] [Accepted: 07/22/2021] [Indexed: 06/13/2023]
Abstract
Searches for the lepton number violating K^{+}→π^{-}μ^{+}e^{+} decay and the lepton flavor violating K^{+}→π^{+}μ^{-}e^{+} and π^{0}→μ^{-}e^{+} decays are reported using data collected by the NA62 experiment at CERN in 2017-2018. No evidence for these decays is found and upper limits of the branching ratios are obtained at 90% confidence level: B(K^{+}→π^{-}μ^{+}e^{+})<4.2×10^{-11}, B(K^{+}→π^{+}μ^{-}e^{+})<6.6×10^{-11} and B(π^{0}→μ^{-}e^{+})<3.2×10^{-10}. These results improve by 1 order of magnitude over previous results for these decay modes.
Collapse
Affiliation(s)
- R Aliberti
- Institut für Physik and PRISMA Cluster of Excellence, Universität Mainz, D-55099 Mainz, Germany
| | - F Ambrosino
- Dipartimento di Fisica "Ettore Pancini" e INFN, Sezione di Napoli, I-80126 Napoli, Italy
| | - R Ammendola
- INFN, Sezione di Roma Tor Vergata, I-00133 Roma, Italy
| | - B Angelucci
- University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - A Antonelli
- Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - G Anzivino
- Dipartimento di Fisica e Geologia dell'Università e INFN, Sezione di Perugia, I-06100 Perugia, Italy
| | - R Arcidiacono
- Dipartimento di Fisica dell'Università e INFN, Sezione di Torino, I-10125 Torino, Italy
| | - T Bache
- University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - A Baeva
- Joint Institute for Nuclear Research, 141980 Dubna (MO), Russia
| | - D Baigarashev
- Joint Institute for Nuclear Research, 141980 Dubna (MO), Russia
| | - M Barbanera
- INFN, Sezione di Perugia, I-06100 Perugia, Italy
| | - J Bernhard
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - A Biagioni
- INFN, Sezione di Roma I, I-00185 Roma, Italy
| | - L Bician
- Faculty of Mathematics, Physics and Informatics, Comenius University, 842 48 Bratislava, Slovakia
| | - C Biino
- INFN, Sezione di Torino, I-10125 Torino, Italy
| | - A Bizzeti
- INFN, Sezione di Firenze, I-50019 Sesto Fiorentino, Italy
| | - T Blazek
- Faculty of Mathematics, Physics and Informatics, Comenius University, 842 48 Bratislava, Slovakia
| | - B Bloch-Devaux
- Dipartimento di Fisica dell'Università e INFN, Sezione di Torino, I-10125 Torino, Italy
| | - V Bonaiuto
- INFN, Sezione di Roma Tor Vergata, I-00133 Roma, Italy
| | - M Boretto
- Dipartimento di Fisica dell'Università e INFN, Sezione di Torino, I-10125 Torino, Italy
| | - A M Bragadireanu
- Horia Hulubei National Institute of Physics for R&D in Physics and Nuclear Engineering, 077125 Bucharest-Magurele, Romania
| | - D Britton
- University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - F Brizioli
- Dipartimento di Fisica e Geologia dell'Università e INFN, Sezione di Perugia, I-06100 Perugia, Italy
| | - M B Brunetti
- University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - D Bryman
- University of British Columbia, Vancouver, British Columbia V6T 1Z4, Canada
| | - F Bucci
- INFN, Sezione di Firenze, I-50019 Sesto Fiorentino, Italy
| | - T Capussela
- Dipartimento di Fisica "Ettore Pancini" e INFN, Sezione di Napoli, I-80126 Napoli, Italy
| | - J Carmignani
- University of Lancaster, Lancaster LA1 4YW, United Kingdom
| | - A Ceccucci
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - P Cenci
- INFN, Sezione di Perugia, I-06100 Perugia, Italy
| | - V Cerny
- Faculty of Mathematics, Physics and Informatics, Comenius University, 842 48 Bratislava, Slovakia
| | - C Cerri
- INFN, Sezione di Pisa, I-56100 Pisa, Italy
| | - B Checcucci
- INFN, Sezione di Perugia, I-06100 Perugia, Italy
| | - A Conovaloff
- George Mason University, Fairfax, Virginia 22030, USA
| | - P Cooper
- George Mason University, Fairfax, Virginia 22030, USA
| | - E Cortina Gil
- Université Catholique de Louvain, B-1348 Louvain-La-Neuve, Belgium
| | - M Corvino
- Dipartimento di Fisica "Ettore Pancini" e INFN, Sezione di Napoli, I-80126 Napoli, Italy
| | - F Costantini
- Dipartimento di Fisica dell'Università e INFN, Sezione di Pisa, I-56100 Pisa, Italy
| | | | - D Coward
- George Mason University, Fairfax, Virginia 22030, USA
| | - G D'Agostini
- Dipartimento di Fisica, Sapienza Università di Roma e INFN, Sezione di Roma I, I-00185 Roma, Italy
| | - J B Dainton
- University of Lancaster, Lancaster LA1 4YW, United Kingdom
| | - P Dalpiaz
- Dipartimento di Fisica e Scienze della Terra dell'Università e INFN, Sezione di Ferrara, I-44122 Ferrara, Italy
| | - H Danielsson
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - N De Simone
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - D Di Filippo
- Dipartimento di Fisica "Ettore Pancini" e INFN, Sezione di Napoli, I-80126 Napoli, Italy
| | - L Di Lella
- Dipartimento di Fisica dell'Università e INFN, Sezione di Pisa, I-56100 Pisa, Italy
| | - N Doble
- Dipartimento di Fisica dell'Università e INFN, Sezione di Pisa, I-56100 Pisa, Italy
| | - V Duk
- University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - F Duval
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - B Döbrich
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - D Emelyanov
- Joint Institute for Nuclear Research, 141980 Dubna (MO), Russia
| | - J Engelfried
- Instituto de Física, Universidad Autónoma de San Luis Potosí, 78240 San Luis Potosí, Mexico
| | - T Enik
- Joint Institute for Nuclear Research, 141980 Dubna (MO), Russia
| | - N Estrada-Tristan
- Instituto de Física, Universidad Autónoma de San Luis Potosí, 78240 San Luis Potosí, Mexico
| | - V Falaleev
- Joint Institute for Nuclear Research, 141980 Dubna (MO), Russia
| | - R Fantechi
- INFN, Sezione di Pisa, I-56100 Pisa, Italy
| | - V Fascianelli
- University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - L Federici
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - S Fedotov
- Institute for Nuclear Research of the Russian Academy of Sciences, 117312 Moscow, Russia
| | - A Filippi
- INFN, Sezione di Torino, I-10125 Torino, Italy
| | - M Fiorini
- Dipartimento di Fisica e Scienze della Terra dell'Università e INFN, Sezione di Ferrara, I-44122 Ferrara, Italy
| | - J R Fry
- University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - J Fu
- University of British Columbia, Vancouver, British Columbia V6T 1Z4, Canada
| | - A Fucci
- INFN, Sezione di Roma Tor Vergata, I-00133 Roma, Italy
| | - L Fulton
- University of Liverpool, Liverpool L69 7ZE, United Kingdom
| | - E Gamberini
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - L Gatignon
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - G Georgiev
- Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - S A Ghinescu
- Horia Hulubei National Institute of Physics for R&D in Physics and Nuclear Engineering, 077125 Bucharest-Magurele, Romania
| | - A Gianoli
- INFN, Sezione di Ferrara, I-44122 Ferrara, Italy
| | - M Giorgi
- Dipartimento di Fisica dell'Università e INFN, Sezione di Pisa, I-56100 Pisa, Italy
| | - S Giudici
- Dipartimento di Fisica dell'Università e INFN, Sezione di Pisa, I-56100 Pisa, Italy
| | - F Gonnella
- University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - E Goudzovski
- University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - C Graham
- University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - R Guida
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - E Gushchin
- Institute for Nuclear Research of the Russian Academy of Sciences, 117312 Moscow, Russia
| | - F Hahn
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - H Heath
- University of Bristol, Bristol BS8 1TH, United Kingdom
| | - J Henshaw
- University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - E B Holzer
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - T Husek
- Charles University, 116 36 Prague 1, Czech Republic
| | - O E Hutanu
- Horia Hulubei National Institute of Physics for R&D in Physics and Nuclear Engineering, 077125 Bucharest-Magurele, Romania
| | - D Hutchcroft
- University of Liverpool, Liverpool L69 7ZE, United Kingdom
| | - L Iacobuzio
- University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - E Iacopini
- Dipartimento di Fisica e Astronomia dell'Università e INFN, Sezione di Firenze, I-50019 Sesto Fiorentino, Italy
| | - E Imbergamo
- Dipartimento di Fisica e Geologia dell'Università e INFN, Sezione di Perugia, I-06100 Perugia, Italy
| | - B Jenninger
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - J Jerhot
- Charles University, 116 36 Prague 1, Czech Republic
| | - R W L Jones
- University of Lancaster, Lancaster LA1 4YW, United Kingdom
| | - K Kampf
- Charles University, 116 36 Prague 1, Czech Republic
| | - V Kekelidze
- Joint Institute for Nuclear Research, 141980 Dubna (MO), Russia
| | - S Kholodenko
- Institute for High Energy Physics-State Research Center of Russian Federation, 142281 Protvino (MO), Russia
| | - G Khoriauli
- Institut für Physik and PRISMA Cluster of Excellence, Universität Mainz, D-55099 Mainz, Germany
| | - A Khotyantsev
- Institute for Nuclear Research of the Russian Academy of Sciences, 117312 Moscow, Russia
| | - A Kleimenova
- Université Catholique de Louvain, B-1348 Louvain-La-Neuve, Belgium
| | - A Korotkova
- Joint Institute for Nuclear Research, 141980 Dubna (MO), Russia
| | - M Koval
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - V Kozhuharov
- Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - Z Kucerova
- Faculty of Mathematics, Physics and Informatics, Comenius University, 842 48 Bratislava, Slovakia
| | - Y Kudenko
- Institute for Nuclear Research of the Russian Academy of Sciences, 117312 Moscow, Russia
| | - J Kunze
- Institut für Physik and PRISMA Cluster of Excellence, Universität Mainz, D-55099 Mainz, Germany
| | - V Kurochka
- Institute for Nuclear Research of the Russian Academy of Sciences, 117312 Moscow, Russia
| | - V Kurshetsov
- Institute for High Energy Physics-State Research Center of Russian Federation, 142281 Protvino (MO), Russia
| | - G Lamanna
- Dipartimento di Fisica dell'Università e INFN, Sezione di Pisa, I-56100 Pisa, Italy
| | - G Lanfranchi
- Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - E Lari
- Dipartimento di Fisica dell'Università e INFN, Sezione di Pisa, I-56100 Pisa, Italy
| | - G Latino
- Dipartimento di Fisica e Astronomia dell'Università e INFN, Sezione di Firenze, I-50019 Sesto Fiorentino, Italy
| | - P Laycock
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - C Lazzeroni
- University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - G Lehmann Miotto
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - M Lenti
- Dipartimento di Fisica e Astronomia dell'Università e INFN, Sezione di Firenze, I-50019 Sesto Fiorentino, Italy
| | - E Leonardi
- INFN, Sezione di Roma I, I-00185 Roma, Italy
| | - P Lichard
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - L Litov
- Joint Institute for Nuclear Research, 141980 Dubna (MO), Russia
| | - R Lollini
- Dipartimento di Fisica e Geologia dell'Università e INFN, Sezione di Perugia, I-06100 Perugia, Italy
| | - D Lomidze
- Institut für Physik and PRISMA Cluster of Excellence, Universität Mainz, D-55099 Mainz, Germany
| | - A Lonardo
- INFN, Sezione di Roma I, I-00185 Roma, Italy
| | - P Lubrano
- INFN, Sezione di Perugia, I-06100 Perugia, Italy
| | - M Lupi
- INFN, Sezione di Perugia, I-06100 Perugia, Italy
| | - N Lurkin
- University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - D Madigozhin
- Joint Institute for Nuclear Research, 141980 Dubna (MO), Russia
| | - I Mannelli
- Scuola Normale Superiore e INFN, Sezione di Pisa, I-56100 Pisa, Italy
| | - A Mapelli
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - F Marchetto
- INFN, Sezione di Torino, I-10125 Torino, Italy
| | - R Marchevski
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - S Martellotti
- Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - P Massarotti
- Dipartimento di Fisica "Ettore Pancini" e INFN, Sezione di Napoli, I-80126 Napoli, Italy
| | - K Massri
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - E Maurice
- University of Liverpool, Liverpool L69 7ZE, United Kingdom
| | - M Medvedeva
- Institute for Nuclear Research of the Russian Academy of Sciences, 117312 Moscow, Russia
| | - A Mefodev
- Institute for Nuclear Research of the Russian Academy of Sciences, 117312 Moscow, Russia
| | - E Menichetti
- Dipartimento di Fisica dell'Università e INFN, Sezione di Torino, I-10125 Torino, Italy
| | - E Migliore
- Dipartimento di Fisica dell'Università e INFN, Sezione di Torino, I-10125 Torino, Italy
| | - E Minucci
- Université Catholique de Louvain, B-1348 Louvain-La-Neuve, Belgium
| | - M Mirra
- Dipartimento di Fisica "Ettore Pancini" e INFN, Sezione di Napoli, I-80126 Napoli, Italy
| | - M Misheva
- Joint Institute for Nuclear Research, 141980 Dubna (MO), Russia
| | - N Molokanova
- Joint Institute for Nuclear Research, 141980 Dubna (MO), Russia
| | - M Moulson
- Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - S Movchan
- Joint Institute for Nuclear Research, 141980 Dubna (MO), Russia
| | - M Napolitano
- Dipartimento di Fisica "Ettore Pancini" e INFN, Sezione di Napoli, I-80126 Napoli, Italy
| | - I Neri
- Dipartimento di Fisica e Scienze della Terra dell'Università e INFN, Sezione di Ferrara, I-44122 Ferrara, Italy
| | - F Newson
- University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - A Norton
- Dipartimento di Fisica e Scienze della Terra dell'Università e INFN, Sezione di Ferrara, I-44122 Ferrara, Italy
| | - M Noy
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - T Numao
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - V Obraztsov
- Institute for High Energy Physics-State Research Center of Russian Federation, 142281 Protvino (MO), Russia
| | - A Ostankov
- Institute for High Energy Physics-State Research Center of Russian Federation, 142281 Protvino (MO), Russia
| | - S Padolski
- Université Catholique de Louvain, B-1348 Louvain-La-Neuve, Belgium
| | - R Page
- University of Bristol, Bristol BS8 1TH, United Kingdom
| | - V Palladino
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - A Parenti
- Dipartimento di Fisica e Astronomia dell'Università e INFN, Sezione di Firenze, I-50019 Sesto Fiorentino, Italy
| | - C Parkinson
- University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - E Pedreschi
- Dipartimento di Fisica dell'Università e INFN, Sezione di Pisa, I-56100 Pisa, Italy
| | - M Pepe
- INFN, Sezione di Perugia, I-06100 Perugia, Italy
| | - M Perrin-Terrin
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - L Peruzzo
- Institut für Physik and PRISMA Cluster of Excellence, Universität Mainz, D-55099 Mainz, Germany
| | - P Petrov
- Université Catholique de Louvain, B-1348 Louvain-La-Neuve, Belgium
| | - Y Petrov
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - F Petrucci
- Dipartimento di Fisica e Scienze della Terra dell'Università e INFN, Sezione di Ferrara, I-44122 Ferrara, Italy
| | - R Piandani
- Dipartimento di Fisica e Geologia dell'Università e INFN, Sezione di Perugia, I-06100 Perugia, Italy
| | - M Piccini
- INFN, Sezione di Perugia, I-06100 Perugia, Italy
| | - J Pinzino
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - I Polenkevich
- Joint Institute for Nuclear Research, 141980 Dubna (MO), Russia
| | - L Pontisso
- INFN, Sezione di Pisa, I-56100 Pisa, Italy
| | - Yu Potrebenikov
- Joint Institute for Nuclear Research, 141980 Dubna (MO), Russia
| | | | - M Raggi
- Dipartimento di Fisica, Sapienza Università di Roma e INFN, Sezione di Roma I, I-00185 Roma, Italy
| | - A Romano
- University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - P Rubin
- George Mason University, Fairfax, Virginia 22030, USA
| | - G Ruggiero
- University of Lancaster, Lancaster LA1 4YW, United Kingdom
| | - V Ryjov
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - A Salamon
- INFN, Sezione di Roma Tor Vergata, I-00133 Roma, Italy
| | - C Santoni
- Dipartimento di Fisica e Geologia dell'Università e INFN, Sezione di Perugia, I-06100 Perugia, Italy
| | - G Saracino
- Dipartimento di Fisica "Ettore Pancini" e INFN, Sezione di Napoli, I-80126 Napoli, Italy
| | - F Sargeni
- INFN, Sezione di Roma Tor Vergata, I-00133 Roma, Italy
| | - S Schuchmann
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - V Semenov
- Institute for High Energy Physics-State Research Center of Russian Federation, 142281 Protvino (MO), Russia
| | - A Sergi
- University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - A Shaikhiev
- Université Catholique de Louvain, B-1348 Louvain-La-Neuve, Belgium
| | - S Shkarovskiy
- Joint Institute for Nuclear Research, 141980 Dubna (MO), Russia
| | - D Soldi
- Dipartimento di Fisica dell'Università e INFN, Sezione di Torino, I-10125 Torino, Italy
| | - M Sozzi
- Dipartimento di Fisica dell'Università e INFN, Sezione di Pisa, I-56100 Pisa, Italy
| | - T Spadaro
- Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - F Spinella
- INFN, Sezione di Pisa, I-56100 Pisa, Italy
| | - A Sturgess
- University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - V Sugonyaev
- Institute for High Energy Physics-State Research Center of Russian Federation, 142281 Protvino (MO), Russia
| | - J Swallow
- University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - S Trilov
- University of Bristol, Bristol BS8 1TH, United Kingdom
| | - P Valente
- INFN, Sezione di Roma I, I-00185 Roma, Italy
| | - B Velghe
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - S Venditti
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - P Vicini
- INFN, Sezione di Roma I, I-00185 Roma, Italy
| | - R Volpe
- Université Catholique de Louvain, B-1348 Louvain-La-Neuve, Belgium
| | - M Vormstein
- Institut für Physik and PRISMA Cluster of Excellence, Universität Mainz, D-55099 Mainz, Germany
| | - H Wahl
- Dipartimento di Fisica e Scienze della Terra dell'Università e INFN, Sezione di Ferrara, I-44122 Ferrara, Italy
| | - R Wanke
- Institut für Physik and PRISMA Cluster of Excellence, Universität Mainz, D-55099 Mainz, Germany
| | - B Wrona
- University of Liverpool, Liverpool L69 7ZE, United Kingdom
| | - O Yushchenko
- Institute for High Energy Physics-State Research Center of Russian Federation, 142281 Protvino (MO), Russia
| | - M Zamkovsky
- Charles University, 116 36 Prague 1, Czech Republic
| | - A Zinchenko
- Joint Institute for Nuclear Research, 141980 Dubna (MO), Russia
| |
Collapse
|
11
|
Abstract
Aims and background Malignant melanoma is one of the most radioresistant tumors. It can be treated with combinated hyperthermia and radiation therapy. Methods From January 1991 through June 1992, 7 patients, 1 male and 6 female, aged 40-88 years (mean 75), with skin and nodal postsurgical recurrences of melanoma, were treated with a combination of radiation therapy and hyperthermia. Two patients presented systemic disease when they reached our observation, but all of them were without symptoms. None of them underwent surgical excision of the recurrence before or during thermoradiotherapy. None received chemotherapy for these recurrences or had received radiotherapy in the past. They were irradiated with electron beams, with electron energies selected according to the depth of the lesions. The total dose was 40 Gy in 10 fractions in 5 weeks. Hyperthermia was administered for 10 minutes to 1 hour after irradiation. An inductive method of radiofrequency heating at 434 of 915 MHz was used depending on the depth of the lesions. In all of these treatments a ionized water bolus was used. The prescribed hyperthermic dose was 42 °C for half a hour. The treatments were carried out twice a week for 5 weeks. A fiberoptic multichannel thermometer was used for thermometry. Results Four patients (57 %) achieved a complete response, 2 patients (29 %) a partial response, and 1 patient (14 %) stabilization. We found no correlation between tumor volume and response rate. Site effects and complications of the treatment were minimal (moderate erythema). Conclusions Our results are in the wide range of values reported in the literature.
Collapse
Affiliation(s)
- M Guenzi
- Department of Radiotherapy, National Cancer Institute of Genoa, Italy
| | | | | | | | | | | | | | | |
Collapse
|
12
|
Lamanna G, Aliberti R, Ambrosino F, Ammendola R, Angelucci B, Antonelli A, Anzivino G, Arcidiacono R, Barbanera M, Biagioni A, Bician L, Biino C, Bizzeti A, Blazek T, Bloch-Devaux B, Bonaiuto V, Boretto M, Bragadireanu M, Britton D, Brizioli F, Brunetti M, Bryman D, Bucci F, Capussela T, Ceccucci A, Cenci P, Cerny V, Cerri C, Checcucci B, Conovaloff A, Cooper P, Cortina Gil E, Corvino M, Costantini F, Cotta Ramusino A, Coward D, D’Agostini G, Dainton J, Dalpiaz P, Danielsson H, De Simone N, Di Filippo D, Di Lella L, Doble N, Dobrich B, Duval F, Duk V, Engelfried J, Enik T, Estrada-Tristan N, Falaleev V, Fantechi R, Fascianelli V, Federici L, Fedotov S, Filippi A, Fiorini M, Fry J, Fu J, Fucci A, Fulton L, Gamberini E, Gatignon L, Georgiev G, Ghinescu S, Gianoli A, Giorgi M, Giudici S, Gonnella F, Goudzovski E, Graham C, Guida R, Gushchin E, Hahn F, Heath H, Husek T, Hutanu O, Hutchcroft D, Iacobuzio L, Iacopini E, Imbergamo E, Jenninger B, Kampf K, Kekelidze V, Kholodenko S, Khoriauli G, Khotyantsev A, Kleimenova A, Korotkova A, Koval M, Kozhuharov V, Kucerova Z, Kudenko Y, Kunze J, Kurochka V, Kurshetsov V, Lanfranchi G, Lamanna G, Latino G, Laycock P, Lazzeroni C, Lenti M, Lehmann Miotto G, Leonardi E, Lichard P, Litov L, Lollini R, Lomidze D, Lonardo A, Lubrano P, Lupi M, Lurkin N, Madigozhin D, Mannelli I, Mannocchi G, Mapelli A, Marchetto F, Marchevski R, Martellotti S, Massarotti P, Massri K, Maurice E, Medvedeva M, Mefodev A, Menichetti E, Migliore E, Minucci E, Mirra M, Misheva M, Molokanova N, Moulson M, Movchan S, Napolitano M, Neri I, Newson F, Norton A, Noy M, Numao T, Obraztsov V, Ostankov A, Padolski S, Page R, Palladino V, Parkinson C, Pedreschi E, Pepe M, Perrin-Terrin M, Peruzzo L, Petrov P, Petrucci F, Piandani R, Piccini M, Pinzino J, Polenkevich I, Pontisso L, Potrebenikov Y, Protopopescu D, Raggi M, Romano A, Rubin P, Ruggiero G, Ryjov V, Salamon A, Santoni C, Saracino G, Sargeni F, Semenov V, Sergi A, Shaikhiev A, Shkarovskiy S, Soldi D, Sougonyaev V, Sozzi M, Spadaro T, Spinella F, Sturgess A, Swallow J, Trilov S, Valente P, Velghe B, Venditti S, Vicini P, Volpe R, Vormstein M, Wahl H, Wanke R, Wrona B, Yushchenko O, Zamkovsky M, Zinchenko A. NA62 and NA48/2 results on search for Heavy Neutral Leptons. EPJ Web Conf 2018. [DOI: 10.1051/epjconf/201817901009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
In this paper we present new results on upper limits for the search of Heavy Neutral Leptons (HNL) with data collected by NA48/2 (2003-2004), NA62-RK (2007) and NA62 (2015) CERN experiments. The data collected with different trigger configuration allow to search for both long and short living heavy neutrinos in the mass range below the kaon mass. In addition the status of the search for K+ → π+vv with the NA62 detector will be briefly presented.
Collapse
|
13
|
Curigliano G, Bagnardi V, Viale G, Fumagalli L, Rotmensz N, Aurilio G, Locatelli M, Pruneri G, Giudici S, Bellomi M, Della Vigna P, Monfardini L, Orsi F, Nolè F, Munzone E, Goldhirsch A. Should liver metastases of breast cancer be biopsied to improve treatment choice? Ann Oncol 2011; 22:2227-33. [DOI: 10.1093/annonc/mdq751] [Citation(s) in RCA: 93] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
14
|
Abstract
An important area of study has examined cognitive aspects of morningness-eveningness orientation. Optimal times of efficiency in participants classified as Morning and Evening types are of great importance for understanding their cognitive abilities. The present review covers the last two decades (1990-2009), during which the important review by Tankova, Adan, and Buela-Casal appeared, and focuses particularly on attention, memory, and executive functions.
Collapse
Affiliation(s)
- G M Cavallera
- Dipartimento di Scienze del Movimento Umano, Facoltà di Scienze dell'Educazione Motoria, Università G. D'Annunzio, Chieti-Pescara, Italy.
| | | | | | | |
Collapse
|
15
|
Montagnana M, Danese E, Giudici S, Franchi M, Guidi GC, Plebani M, Lippi G. HE4 in ovarian cancer: from discovery to clinical application. Adv Clin Chem 2011; 55:1-20. [PMID: 22126021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
Despite the relatively low prevalence, ovarian cancer is the fifth leading cause of death from cancer among women. As such, an early diagnosis for establishing a timely surgical and/or chemotherapeutic treatment is essential for improving the outcome. The most reliable, but not always straightforward, approach to diagnose ovarian cancer relies on multiple, time-consuming and expensive investigative tools. These typically include clinical presentation (i.e., pelvic or abdominal pain, urinary frequency or urgency, increased abdominal size or bloating) with pelvic examination, transvaginal ultrasonography (US), and measurement of carbohydrate antigen 125 (CA125). Although the conventional pathway to develop and market a clinically useful biomarker is challenging, recent advances in genomic and proteomic technologies have led to the identification of previously unknown candidate markers of ovarian cancer. Some of these are currently under clinical validation. The human epididymis protein 4 (HE4) has recently been approved by the Food and Drug Administration for monitoring recurrence or progression of epithelial ovarian cancer. Nevertheless, reliable clinical evidence demonstrates that HE4, used alone or in combination with CA125, substantially improves the accuracy of screening and/or disease monitoring. This chapter will review the current knowledge on biologic and clinical applications of ovarian cancer biomarkers, with particular emphasis on the newly proposed marker, HE4.
Collapse
Affiliation(s)
- M Montagnana
- Clinical Biochemistry Laboratory, Department of Life and Reproduction Sciences, University Hospital of Verona, Verona, Italy.
| | | | | | | | | | | | | |
Collapse
|
16
|
|
17
|
Fumagalli L, Curigliano G, Locatelli M, Bagnardi V, Bertolini F, Mancuso P, Giudici S, Goldhirsch A. Abstract P6-12-06: Oral Vinorelbine and Capecitabine Plus Bevacizumab in Recurrent Inflammatory Breast Cancer: Gene Profiling and Response to Treatment. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p6-12-06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Therapies that target vasculolymphatic processes - angiogenesis, lymphangiogenesis, and vasculogenesis — have shown potential in the treatment of inflammatory breast cancer.
Methods: We randomly assigned 46 patients to receive oral vinorelbine 55 mg per square meter of body surface on days 1 and 3 and capecitabine 2000 mg per square meter on days 1 to 14 every 3 weeks either concurrent or sequential to bevacizumab 15 mg per kilogram of body weight on days 1 and 21 (BEVIX). The primary end point was progression-free survival;
the response rate and overall survival were a secondary end point. For correlative studies we collected baseline tissue and blood samples of all patients. Gene expression profiling was performed using Affymetrix HG-U133 Plus 2.0 arrays. Data were analyzed using Partek Genomic Suite 6.4 and GeneSpring 7.0. Tissue from normal breast was used as control.
Results: From July 2007 through January 2010, a total of 46 patients were enrolled. Concurrent oral vinorelbine and capecitabine plus bevacizumab significantly increased the objective response rate as compared to the sequential treatment (11.1% vs. 46.4%, p=0.025). No difference in progression-free survival was observed between the two arms (median time to progression 4.3 vs. 4.7 months, p=0.69; Hazard Ratio: 0.86, 95% CI: 0.41-1.80). The median overall survival was 9.1 months in concurrent arm and 15.8 months in sequential arm, (p=0.43). Global gene expression was analyzed in tumor samples from 18 pts bearing a triple negative phenotype. This cohort displayed a specific gene expression profile, including high expression levels of several cytokeratins, Aurora kinase A, Cyclin E and others, similar to the basal-like subtype. This profile did not include genes previously reported as differentially expressed in inflammatory breast cancers. We identified a set of 75 genes whose expression correlates with response to bevacizumab base therapy.
Conclusions: BEVIX is an active treatment for patients with recurrent inflammatory breast cancer. These tumors showed a gene expression pattern similar to that of basal-like type. We identified a set of 75 genes whose expression levels predict the response to BEVIX. The validity of this expression signature is currently being assessed. Supported by Roche and Associazione Italiana per la Ricerca sul Cancro (AIRC) grants. Data partially submitted to 2010 ASCO Meeting
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P6-12-06.
Collapse
Affiliation(s)
- L Fumagalli
- Istituto Europeo di Oncologia, Milano, Italy; University of Milano Bicocca and Frontier Science Foundation Southern Europe, Italy; Istituto Europeo di Oncologa, Milano, Italy
| | - G Curigliano
- Istituto Europeo di Oncologia, Milano, Italy; University of Milano Bicocca and Frontier Science Foundation Southern Europe, Italy; Istituto Europeo di Oncologa, Milano, Italy
| | - M Locatelli
- Istituto Europeo di Oncologia, Milano, Italy; University of Milano Bicocca and Frontier Science Foundation Southern Europe, Italy; Istituto Europeo di Oncologa, Milano, Italy
| | - V Bagnardi
- Istituto Europeo di Oncologia, Milano, Italy; University of Milano Bicocca and Frontier Science Foundation Southern Europe, Italy; Istituto Europeo di Oncologa, Milano, Italy
| | - F Bertolini
- Istituto Europeo di Oncologia, Milano, Italy; University of Milano Bicocca and Frontier Science Foundation Southern Europe, Italy; Istituto Europeo di Oncologa, Milano, Italy
| | - P Mancuso
- Istituto Europeo di Oncologia, Milano, Italy; University of Milano Bicocca and Frontier Science Foundation Southern Europe, Italy; Istituto Europeo di Oncologa, Milano, Italy
| | - S Giudici
- Istituto Europeo di Oncologia, Milano, Italy; University of Milano Bicocca and Frontier Science Foundation Southern Europe, Italy; Istituto Europeo di Oncologa, Milano, Italy
| | - A. Goldhirsch
- Istituto Europeo di Oncologia, Milano, Italy; University of Milano Bicocca and Frontier Science Foundation Southern Europe, Italy; Istituto Europeo di Oncologa, Milano, Italy
| |
Collapse
|
18
|
Locatelli MA, Curigliano G, Fumagalli L, Bagnardi V, Aurilio G, Della Vigna P, Monfardini L, Giudici S, Viale G, Goldhirsch A. Should liver metastases of breast cancer be biopsied to improve treatment choice? J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.18_suppl.cra1008] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
CRA1008 Background: Decision making on systemic treatment of women with metastatic breast cancer is based on features like estrogen receptor (ER), progesterone receptor (PgR), and HER2 status assessed on the primary tumor. We evaluated the concordance of receptor status between primary tumor and liver metastases (mts) and its impact on treatment choice. Methods: We retrospectively analyzed a database including ultrasound guided liver biopsies performed from 1995 to 2008. All tissue samples, both from primary tumor and liver mts, were analyzed for ER, PgR and HER2 status. Clinical and biological data were obtained from medical charts. Differences between proportions were evaluated using the Pearson chi-square test. Results: We identified 255 consecutive patients (pts) with matched primary and liver tissue samples. Median time from primary diagnosis to liver biopsy was 3.4 years (range 0-18.3 years). Changes in ER status were observed in 41/255 pts (16.0%). 16/58 pts (27.6%) changed from ER-negative to ER-positive and 25/197 pts (12.7%) changed from ER-positive to ER-negative (p=0.0066). Changes in PgR status were observed in 76/255 pts (29.8%). 18/91 pts (19.8%) changed from PgR-negative to -positive and 58/164 pts (64.6%) from PgR-positive to PgR-negative (p <0.0001). 12/52 pts (23.1%) changed from ER- and PgR-negative to ER- or PgR-positive (group A) and 27/203 pts (13.3%) changed from ER- or PgR-positive to ER- and PgR-negative (group B) (p=0.087). In the group A the treatment of 4/12 pts (33.3%) was changed after biopsy: 2/4 started endocrine treatment (HT) and 2/4 stopped it. In group B the treatment of 18/27 pts (66.6%) was changed after biopsy: 17/18 stopped HT. Changes in HER2 status were observed in 22/167 pts (13.1%): 6/116 pts (5.1%) changed from HER2-negative to HER2-positive and 16/51 pts (31.4%) changed from HER2-positive to negative (p≤0.0001). In this group pts started and/or stopped a trastuzumab containing treatment after biopsy. Conclusions: There was a discordance in receptor status between primary tumor and liver mts, which led to change in therapy for 48/255 of pts (18.8%). Biopsy of metastases for reassessment of biological features should be considered in all pts when safe and easy to perform, since it is likely to impact treatment choice. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- M. A. Locatelli
- Division of Medical Oncology, European Institute of Oncology, Milan, Italy; Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy; Division of Radiology, European Institute of Oncology, Milan, Italy; Division of Pathology, European Institute of Oncology, Milan, Italy; International Breast Cancer Study Group, Bern, Switzerland
| | - G. Curigliano
- Division of Medical Oncology, European Institute of Oncology, Milan, Italy; Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy; Division of Radiology, European Institute of Oncology, Milan, Italy; Division of Pathology, European Institute of Oncology, Milan, Italy; International Breast Cancer Study Group, Bern, Switzerland
| | - L. Fumagalli
- Division of Medical Oncology, European Institute of Oncology, Milan, Italy; Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy; Division of Radiology, European Institute of Oncology, Milan, Italy; Division of Pathology, European Institute of Oncology, Milan, Italy; International Breast Cancer Study Group, Bern, Switzerland
| | - V. Bagnardi
- Division of Medical Oncology, European Institute of Oncology, Milan, Italy; Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy; Division of Radiology, European Institute of Oncology, Milan, Italy; Division of Pathology, European Institute of Oncology, Milan, Italy; International Breast Cancer Study Group, Bern, Switzerland
| | - G. Aurilio
- Division of Medical Oncology, European Institute of Oncology, Milan, Italy; Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy; Division of Radiology, European Institute of Oncology, Milan, Italy; Division of Pathology, European Institute of Oncology, Milan, Italy; International Breast Cancer Study Group, Bern, Switzerland
| | - P. Della Vigna
- Division of Medical Oncology, European Institute of Oncology, Milan, Italy; Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy; Division of Radiology, European Institute of Oncology, Milan, Italy; Division of Pathology, European Institute of Oncology, Milan, Italy; International Breast Cancer Study Group, Bern, Switzerland
| | - L. Monfardini
- Division of Medical Oncology, European Institute of Oncology, Milan, Italy; Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy; Division of Radiology, European Institute of Oncology, Milan, Italy; Division of Pathology, European Institute of Oncology, Milan, Italy; International Breast Cancer Study Group, Bern, Switzerland
| | - S. Giudici
- Division of Medical Oncology, European Institute of Oncology, Milan, Italy; Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy; Division of Radiology, European Institute of Oncology, Milan, Italy; Division of Pathology, European Institute of Oncology, Milan, Italy; International Breast Cancer Study Group, Bern, Switzerland
| | - G. Viale
- Division of Medical Oncology, European Institute of Oncology, Milan, Italy; Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy; Division of Radiology, European Institute of Oncology, Milan, Italy; Division of Pathology, European Institute of Oncology, Milan, Italy; International Breast Cancer Study Group, Bern, Switzerland
| | - A. Goldhirsch
- Division of Medical Oncology, European Institute of Oncology, Milan, Italy; Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy; Division of Radiology, European Institute of Oncology, Milan, Italy; Division of Pathology, European Institute of Oncology, Milan, Italy; International Breast Cancer Study Group, Bern, Switzerland
| |
Collapse
|
19
|
Curigliano G, Alkalay M, Locatelli MA, Fumagalli L, Giudici S, Bertolini F, Galimberti V, Viale G, Nole F, Goldhirsch A. Genetic signature of breast cancer with lymphangitic spread to the chest wall: Results from a randomized phase II study combining bevacizumab with oral vinorelbine plus capecitabine (BEVIX). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.1078] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
20
|
Fumagalli L, Curigliano G, Bagnardi V, Locatelli M, Aurilio G, Della Vigna P, Monfardini L, Giudici S, Viale G, Toppo L, Goldhirsch A. Should Liver Metastases of Breast Cancer Be Biopsied To Improve Treatment Choice? Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-09-6003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Decision making on systemic treatment of women with metastatic breast cancer is based on features like estrogen receptor (ER), progesterone receptor (PgR), and HER2 status assessed on the primary tumor. We evaluated the concordance of receptor status between primary tumor and liver metastases and estimated the potential change of these pathological features and its impact on treatment choice.Materials and methods: We retrospectively analyzed a database including ultrasound guided liver biopsies performed from 1995 to 2008. All tissue samples, both from primary tumor and liver metastases, were analyzed for ER, PgR and HER2 status. Clinical and biological data were obtained from medical charts (including treatments before and after liver biopsy). Differences between proportions were evaluated using the Pearson chi-square test.Results: We identified 215 consecutive patients with matched primary and liver tissue samples. Median time from primary diagnosis to liver biopsy was 4.1 years (range 0-18.3 years). Changes in ER status were observed in 38/215 patients (17.7%). 15/47 patients (31.9%) changed from ER negative to positive and 23/168 patients (13.7%) changed from ER positive to negative [p= 0.0038]. Changes in PgR status were observed in 111/215 patients (51.6%). 16/74 patients (21.6%) changed from PgR negative to positive and 95/141 patients (67.4%) from PgR positive to negative [p <0.0001]. 11/41 patients (26.8%) changed from ER and PgR negative to ER or PgR positive [Group A] and 25/174 patients (14.4%) changed from ER or PgR positive to ER and PgR negative [Group B] [p=0.054]. In the Group A the treatment of 4/11 patients (36.4%) was changed after biopsy: 2/4 started endocrine treatment (HT) and 2/4 stopped it. In Group B the treatment of 16/25 patients (64%) was changed after biopsy: 15/16 stopped HT. Changes in HER2 status were observed in 19/131 patients (14.5%): 5/93 patients (5.4%) changed from HER2 negative to positive and 14/38 patients (36.8%) changed from HER2 positive to negative [p= <0.0001]. In this group 5/5 patients started a trastuzumab containing treatment after biopsy.Conclusions: There was a substantial discordance in receptor status between primary tumor and liver metastases, which led to change in therapy for 21.8 % of patients. Biopsy of metastases for reassessment of biological features should be considered in all patients when safe and easy to perform, since it might impact treatment choice for many.
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 6003.
Collapse
Affiliation(s)
| | | | - V. Bagnardi
- 2European Institute of Oncology, Italia, Italy
| | | | - G. Aurilio
- 1European Institute of Oncology, Italia, Italy
| | | | | | - S. Giudici
- 1European Institute of Oncology, Italia, Italy
| | - G. Viale
- 4European Institute of Oncology, Italia, Italy
| | - L. Toppo
- 1European Institute of Oncology, Italia, Italy
| | | |
Collapse
|
21
|
|
22
|
Comparetto C, Giudici S, Coccia ME, Scarselli G, Borruto F. Clinical, ethical, and medical legal considerations on emergency contraception. CLIN EXP OBSTET GYN 2005; 32:107-10. [PMID: 16108393] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/04/2023]
Abstract
PURPOSE OF INVESTIGATION To evaluate how many women required the so-called "emergency contraception" at our outpatient service and what the actual role is of this kind of pharmacological administration in interfering with ovulation and pregnancy, paying particular attention to the ethical and medico-legal aspects of this subject. METHODS During the period from 1 December 1998 to 30 November 2003, emergency contraception was prescribed to a total of 1,160 women. With regard to the contraceptives used, in most cases (1,132, 97.6%) a combined oral estrogen-progestogen pill (ethinyloestradiol 0.05 mg plus levonorgestrel 0.25 mg) was prescribed; in some cases (20 patients, 1.8%) danazol (400 mg), in four women (0.3%) a progestin-only pill (levonorgestrel 0.75 mg), and in four other women (0.3%) an intrauterine device. RESULTS It does not come out that there were any pregnancies in our study patients since none of them, who were told to come back for follow-up, were seen at our termination of pregnancy service or delivery room. CONCLUSION The "Yuzpe regimen" of a combined oral estrogen-progestogen pill has been the most commonly used method for emergency contraception. A new method recently proposed, a progestin-only pill with levonorgestrel 0.75 mg, is having better results than the previous one, with a lower incidence of side-effects and higher efficacy. Moreover, the treatment with this method does not interfere in case of a pregnancy already being carried and cannot interrupt it.
Collapse
Affiliation(s)
- C Comparetto
- Division of Obstetrics and Gynaecology, City Hospital, Prato Italy
| | | | | | | | | |
Collapse
|
23
|
Comparetto C, Giudici S, Coccia ME, Scarselli G, Borruto F. Fetal and neonatal ovarian cysts: what's their real meaning? CLIN EXP OBSTET GYN 2005; 32:123-5. [PMID: 16108397] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/04/2023]
Abstract
PURPOSE OF INVESTIGATION The management of fetal ovarian cysts is still controversial despite the improvement in prenatal diagnosis with ultrasonography. Some studies suggest an aggressive management, while others opt for a conservative one. The prognosis of the majority of congenital ovarian cysts is good since they have a benign origin. Sometimes, however, complications such as torsion or rupture can occur which often require surgical intervention after delivery. In this paper we report our experience and a brief review of the literature. METHODS The authors report on 32 pregnant women in whom ultrasonography revealed the presence of an echo-rare or echo-free area in the fetal abdomen suggestive of an ovarian cyst. All women were followed-up during pregnancy with serial ultrasound examinations. Postnatal ultrasound controls confirmed the prenatal diagnosis in all cases. The diameters of the cysts ranged from 2.7 to 7.5 cm. RESULTS In the 16 cases (50%) in which the cyst diameter was below 4 cm, periodic ultrasound examinations revealed a tendency towards spontaneous regression of the cysts. In the other 16 cases (50%) in which the cyst diameter exceeded 4 cm, cystectomy was necessary due to subsequent complications (torsion in 6 cases, 37.5%, and intracystic hemorrhage in the other 10, 62.5%). CONCLUSION The most appropriate clinical approach in the management of benign feto-neonatal ovarian cysts is to adopt a wait-and-see policy, assessing the course of the condition by means of periodic ultrasound monitoring. Only when tumefactions measure more than 4 cm in diameter with attendant complications is surgical therapy indicated. Without complications, however, aspiration of the cystic contents is possible even in ovarian cysts exceeding 4 cm in diameter.
Collapse
Affiliation(s)
- C Comparetto
- Division of Obstetrics and Gynaecology, City Hospital, Prato, Italy
| | | | | | | | | |
Collapse
|
24
|
Giudici S, Farmer W, Dollinger A, Andrada T, Torrington K, Rajagopal K. Lack of predictive value of the Epworth Sleepiness Scale in patients after uvulopalatopharyngoplasty. Ann Otol Rhinol Laryngol 2000; 109:646-9. [PMID: 10903045 DOI: 10.1177/000348940010900706] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
The Epworth Sleepiness Scale (ESS) has been recognized as a valid measure of sleep propensity. Statistically significant correlations between ESS scores, the respiratory disturbance index (RDI), and the lowest arterial oxygen saturation (LSAT) have been described in patients with surgically untreated obstructive sleep apnea (OSA). We investigated whether the same relationships hold true after uvulopalatopharyngoplasty (UPPP). Forty-two adults with documented OSA treated by UPPP were reevaluated with the ESS questionnaire and 8-hour diagnostic nocturnal polysomnography (nPSG). We found no significant correlation between the ESS scores and the RDI or LSAT in patients after UPPP. Because postoperative ESS scores do not correlate with the RDI or LSAT, we conclude that the ESS is not a reliable surrogate for nPSG testing.
Collapse
Affiliation(s)
- S Giudici
- Pulmonary and Critical Care Medicine Service, Walter Reed Army Medical Center, Washington, DC, USA
| | | | | | | | | | | |
Collapse
|
25
|
Ardizzoni A, Grossi F, Scolaro T, Giudici S, Foppiano F, Boni L, Tixi L, Cosso M, Mereu C, Ratto GB, Vitale V, Rosso R. Induction chemotherapy followed by concurrent standard radiotherapy and daily low-dose cisplatin in locally advanced non-small-cell lung cancer. Br J Cancer 1999; 81:310-5. [PMID: 10496358 PMCID: PMC2362873 DOI: 10.1038/sj.bjc.6990693] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Abstract
Both induction chemotherapy and concurrent low-dose cisplatin have been shown to improve results of thoracic irradiation in the treatment of locally advanced non-small-cell lung cancer (NSCLC). This phase II study was designed to investigate activity and feasibility of a novel chemoradiation regimen consisting of induction chemotherapy followed by standard radiotherapy and concurrent daily low-dose cisplatin. Previously untreated patients with histologically/cytologically proven unresectable stage IIIA/B NSCLC were eligible. Induction chemotherapy consisted of vinblastine 5 mg m(-2) intravenously (i.v.) on days 1, 8, 15, 22 and 29, and cisplatin 100 mg m(-2) i.v. on days 1 and 22 followed by continuous radiotherapy (60 Gy in 30 fractions) given concurrently with daily cisplatin at a dose of 5 mg m(-2) i.v. Thirty-two patients were enrolled. Major toxicity during induction chemotherapy was haematological: grade III-IV leukopenia was observed in 31% and grade II anaemia in 16% of the patients. The most common severe toxicity during concurrent chemoradiation consisted of grade III leukopenia (21% of the patients); grade III oesophagitis occurred in only two patients and pulmonary toxicity in one patient who died of this complication. Eighteen of 32 patients (56%, 95% CI 38-73%) had a major response (11 partial response, seven complete response). With a median follow-up of 38.4 months, the median survival was 12.5 months and the actuarial survival rates at 1, 2 and 3 years were 52%, 26% and 19% respectively. The median event-free survival was 8.3 months with a probability of 40%, 23% and 20% at 1, 2 and 3 years respectively. Induction chemotherapy followed by concurrent daily low-dose cisplatin and thoracic irradiation, in patients with locally advanced NSCLC, is active and feasible with minimal non-haematological toxicity. Long-term survival results are promising and appear to be similar to those of more toxic chemoradiation regimens, warranting further testing of this novel chemoradiation strategy.
Collapse
Affiliation(s)
- A Ardizzoni
- Division of Medical Oncology I, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Ardizzoni A, Grossi F, Scolaro D, Giudici S, Pennucci C, Cafferata M, Tixi L, Vitale V, Rosso R. 252 Combination chemotherapy followed by daily cisplatin and concurrent high dose radiotherapy: A phase II study in unresectable non-small cell lung cancer (NSCLC). Lung Cancer 1997. [DOI: 10.1016/s0169-5002(97)89632-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
27
|
Sanguineti G, Orsatti M, Sormani MP, Canobbio L, Curotto A, Tognoni P, Giudici S, Franzone P, Boccardo F, Vitale V. Predictive factors for outcome in invasive bladder cancer treated with alternating chemoradiotherapy. Cancer J Sci Am 1997; 3:213-23. [PMID: 9263627] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
PURPOSE In order to select patients properly for a bladder preservation program, this retrospective study aimed to evaluate the predictive role of pretreatment- and treatment-related factors in a group of patients with invasive bladder cancer treated with alternating chemoradiotherapy at a single institution. METHODS AND MATERIALS From 1986 to 1994, 72 patients with invasive bladder cancer, stages T1 poorly differentiated or T2-4M0 refusing surgery or not eligible for surgery, were treated with alternating chemoradiotherapy. Each patient had a pretreatment cystoscopy with an attempted complete transurethral resection of the bladder tumor (TURB). The treatment schedule consisted of chemotherapy (cisplatin, 5-fluorouracil, or methotrexate) alternated with radiotherapy. Over the years, the treatment schedule was modified with respect to the total number of chemotherapy cycles, the type of chemotherapy drugs, the dose per fraction and total dose of radiation therapy, and the presence of a planned treatment gap at midtreatment. Treatments were aligned in order of their received average relative dose intensities of both chemotherapy (ARDICT) and radiotherapy (RDIRT). RESULTS Twenty-two patients (76%) developed infiltrative bladder recurrences for an estimated 5-year pelvic control rate of 68% +/- 6%; 5-year actuarial survival with intact bladder is 40% +/- 6%. Obstructive uropathy at diagnosis, residual disease after TURB, and ARDICT value equal or below the median were independent predictive factors for pelvic failure, with hazard ratios of 2.87 (95% confidence interval [CI], 1.16-7.04), 8.13 (95% CI, 2.74-24.1), and 3.36 (95% CI, 1.29-8.74), respectively. A more detailed model including interactions among these factors showed that the negative prognostic effect of obstructive uropathy at diagnosis was not modified by ARDICT or TURB resection; on the contrary, the risk of local failure for patients with incomplete TURB was markedly affected by different levels of ARDICT. Also, a trend toward a better local outcome was observed for patients with RDIRT above the median. Hydronephrosis and incomplete TURB were also independent predictors of distant metastases and overall survival, but no effect was found for ARDICT on these endpoints. DISCUSSION As a result of this analysis we believe that (1) patients with obstructive uropathy should not be offered a bladder-sparing approach, (2) gross total TURB of the primary tumor should be maximized, (3) prompt surgery should be considered for patients with incomplete TURB who are not compliant with the combined-modality treatment, and (4) the intrinsic value of dose intensity of both chemotherapy and radiotherapy should be confirmed in a prospective, controlled study.
Collapse
Affiliation(s)
- G Sanguineti
- Department of Radiation Oncology, University of Genoa, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Conio M, Picasso M, Orsatti M, Pugliese V, Camoriano A, Giudici S, Aste H. Combined treatment with lasertherapy (Nd:YAG) and endocavitary radiation in the palliation of rectal cancer. Hepatogastroenterology 1996; 43:1518-22. [PMID: 8975958] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
BACKGROUND/AIMS The ideal treatment for patients with advanced rectal cancer and who cannot undergo a radical therapy is still undefined. The association between lasertherapy (LT) and internal radiotherapy (IRT) could affect both technical results and quality of life. This study was aimed at evaluating the association of LT and IRT in the palliative treatment of rectal cancer. MATERIAL AND METHODS Between January and April 1994, 9 patients (2 males, 7 females) with rectal cancer underwent a combined treatment modality in order to control their symptoms. All patients were unfit for surgery and EUS showed an invasion of the whole muscular layer. After laser recanalization, brachytherapy was applied at a one week interval from last laser session. Two fractions of 10 Gy were administered at one week intervals. RESULTS The mean number of laser sessions to obtain a complete recanalization was 3 (range:2-5) and no complications occurred. After IRT, we obtained a good result in 7/9 patients (79%) and 2 patients required further LT. The mean follow-up was 146 days (range:74-240): during this period no laser treatment was performed. Four patients complained of acute perineal pain and tenesmus after brachytherapy: in one patient, a colostomy was performed. CONCLUSION We deem that the administration of two fractions of 10 Gy is not advisable, particularly for the treatment of non-circumferential lesions, due to the severe side effects we observed.
Collapse
Affiliation(s)
- M Conio
- Department of Gastroenterology, National Institute for Cancer Research, Genoa, Italy
| | | | | | | | | | | | | |
Collapse
|
29
|
Scolaro T, Bacigalupo A, Giudici S, Guenzi M, Vitale V. [Single-dose palliative radiotherapy in inoperable non-small-cell lung carcinoma]. Radiol Med 1995; 90:808-11. [PMID: 8685468] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
The treatment of choice for advanced inoperable non-small cell lung cancer (NSCLC) is radiation therapy. Palliative radiotherapy schedules vary considerably in different centers, but a 30-Gy dose given in ten fractions over two weeks is a typical standard schedule. Our study was aimed at investigating whether a shorter course of only one 10-Gy fraction allows good palliation in the treatment of inoperable NSCLC patients whose main symptoms are related to an intrathoracic lesion. Patients of both sexes and any age, untreated with radiotherapy, with inoperable and histologically or cytologically proved NSCLC were examined. Seventeen patients, too advanced for radical "curative" radiotherapy and whose main symptoms were related to primary intrathoracic lesions, entered the study even though they had metastases. On admission, 76% (13/17) of patients had cough 76% (13/17) dyspnea, 70.7% (12/17) chest pain and 23.6% (4/17) hemoptysis. They received a single dose of 10 Gy, delivered with an 18-Mv linear accelerator via anteroposteriorly opposing portals without spinal cord shielding. Treatment volume usually included the macroscopically detected lesion identified with a CT simulator. Palliation of symptoms was achieved in high rates of patients: 46% for cough, 69% for dyspnea, 83% for pain and 75% for hemoptysis. These results were obtained within one month of treatment. Unfortunately, palliation of symptoms did not last long, decreasing to 42% within two months of the end of treatment and to 32% at three months. Four patients were retreated, one patient three months and three patients two months after the end of radiotherapy. Ten Gy to the target volume were administered as retreatment with spinal cord shielding. Side-effects were mild: nausea in 3 patients (17%), vomiting in one patient (5%) and grade-II dysphagia in two patients were observed and classified according to WHO criteria. Pain increased 24 hours after radiotherapy in five patients. We can conclude that single dose radiotherapy yields good, but short, palliation of symptoms with acceptable side-effects.
Collapse
Affiliation(s)
- T Scolaro
- Servizio di Oncologia Radioterapica, Istituto Nazionale per la Ricerca sul Cancro, Genova
| | | | | | | | | |
Collapse
|
30
|
Orsatti M, Vitale V, Curotto A, Canobbio L, Scarpati D, Franzone P, Giudici S, Guarneri D, Martorana G, Boccardo F. 1161 Alternating chemo-radiotherapy in bladder cancer: A conservative approach. Eur J Cancer 1995. [DOI: 10.1016/0959-8049(95)96407-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
31
|
Orsatti M, Curotto A, Canobbio L, Guarneri D, Scarpati D, Venturini M, Franzone P, Giudici S, Martorana G, Boccardo F. Alternating chemo-radiotherapy in bladder cancer: a conservative approach. Int J Radiat Oncol Biol Phys 1995; 33:173-8. [PMID: 7642415 DOI: 10.1016/0360-3016(95)00136-m] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
PURPOSE The aim of this Phase II study was to determine a bladder-sparing treatment in patients with invasive bladder cancer, allowing a better quality of life. Objectives were to test toxicity and disease-free and overall survival of patients given an alternated chemo-radiotherapy definitive treatment. METHODS AND MATERIALS Seventy-six patients with bladder cancer Stage T1G3 through T4 N0 M0 were entered in the same chemotherapy regimen (Cisplatin 20 mg/mq and 5-Fluorouracil 200 mg/mq daily for 5 days) alternated with different radiotherapy scheduling, the first 18 patients received two cycles of 20 Gy/10 fractions/12 days each; the second group of 58 patients received two cycles of 25 Gy/10 fractions/12 days each (the last 21 patients received Methotrexate 40 mg/mq instead of 5-Fluorouracil). RESULTS A clinical complete response was observed in 57 patients (81%), partial response in 7 patients (10%), and a nonresponse in 6 patients (9%). At a median follow-up of 45 months, 33 patients (47%) were alive and free of tumor. The 6-year overall survival and progression-free survival was 42% and 40%, respectively. Systemic side effects were mild, while a moderate or severe local toxicity was observed in 14 patients and 13 patients (about 20%), respectively. CONCLUSION Our conservative combination treatment allowed bladder-sparing in a high rate of patients and resulted in a survival comparable to that reported after radical cystectomy.
Collapse
Affiliation(s)
- M Orsatti
- Istituto Nazionale per la Ricerca sul Cancro, Genova
| | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Campora E, Giudici S, Merlini L, Rubagotti A, Rosso R. Ondansetron and dexamethasone versus standard combination antiemetic therapy. A randomized trial for the prevention of acute and delayed emesis induced by cyclophosphamide-doxorubicin chemotherapy and maintenance of antiemetic effect at subsequent courses. Am J Clin Oncol 1994; 17:522-6. [PMID: 7977174] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
The antiemetic efficacy of ondansetron and dexamethasone (Ondex) was randomly compared to that of high-dose metoclopramide, dexamethasone, and orphenadrine (Control) in the prevention of emesis induced by cyclophosphamide-doxorubicin chemotherapy in 64 chemotherapy-naive breast cancer patients. For the control of acute emesis (day 1), patients were randomized to receive either ondasetron 8 mg p.o. 1 hour prior to chemotherapy (CT) and repeated after 6 and 12 hours plus dexamethasone 20 mg i.v. 40 minutes prior to CT (Ondex) or dexamethasone 20 mg i.v. 40 minutes prior to CT, orphenadrine 40 mg i.m. 35 minutes prior to CT and metoclopramide 3 mg/kg i.v. 30 minutes prior to CT and repeated after 90 minutes followed by 40 mg p.o. every 3 hours for 4 times (Control). To control delayed emesis, patients on Ondex received ondansetron 8 mg PO t.i.d. days 2 and 3 and patients in the Control arm received metoclopramide 0.5 mg/kg p.o. q.i.d. and dexamethasone 8 mg i.m. b.i.d. days 2 and 3. Complete and major control of acute emesis was observed in 74%/94% and 44%/67% of patients treated with Ondex and Control, respectively (p < .01/p < .005). Acute nausea was absent in 38% and 34% of patients treated with Ondex and Control, respectively (p = NS). Complete and major control of delayed emesis (days 2-5) was observed in 65%/91% versus 44%/66% of patients in the Ondex and Control arms, respectively (p = NS/p < .01). In patients receiving 6 courses of FEC/FAC, control of acute emesis was significantly superior with Ondex at all treatment courses.
Collapse
Affiliation(s)
- E Campora
- Department of Medical Oncology, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
| | | | | | | | | |
Collapse
|
33
|
Repetto L, Miglietta L, Gardin G, Lanfranco C, Naso C, Merlini L, Giudici S, Venturino A, Campora E, Testore F. Phase II study of weekly mitoxantrone, 5-fluorouracil, and leucovorin in metastatic breast cancer. Breast Cancer Res Treat 1994; 30:133-7. [PMID: 7949211 DOI: 10.1007/bf00666056] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
A phase II study to test the toxicity and the efficacy of a weekly combination of Mitoxantrone, 5-Fluorouracil and L-Leucovorin (MFL) was carried out in 43 patients with metastatic breast cancer. Chemotherapy consisted of mitoxantrone 4 mg/m2, 5-fluorouracil 375 mg/m2, and L-leucovorin 100 mg/m2 on day 1, weekly. Patient characteristics were: median age 53 years (range 36-65); estrogen receptor (ER) status was known in 26 patients and of these 15 (57.7%) patients were ER-positive and 11 (42.3%) ER-negative. Of the 43 patients, 25 (58.1%) and 18 (41.9%) patients had received prior adjuvant chemotherapy and prior adjuvant endocrine treatment, respectively. MFL was administered to 22 (51.1%) patients as first line chemotherapy for advanced disease, while 21 (48.9%) patients had received 1 to 2 cytotoxic regimens for metastatic disease. The dominant sites of metastases were: soft tissue in 11 (25.5%) patients, bone in 8 (18.6%) patients and viscera in 24 (55.9%). All patients were assessable for toxicity: only 8 patients experienced WHO grade 3 leukopenia. Thrombocytopenia, diarrhea, stomatitis, and nausea/vomiting were negligible. Anemia and alopecia were not observed. Thirty-nine patients were assessable for response: overall response rate was 28.2% (complete response 7.7% and partial response 20.5%). Median duration of response was 12 months (range 6-34). Patients with no prior anthracyclines had a 42.1% response rate compared to 15% in patients who had received anthracyclines. Median overall survival of the 43 patients was 6 months (range 1-34). Weekly MFL is a well-tolerated and a moderately effective regimen for the treatment of metastatic breast cancer.
Collapse
Affiliation(s)
- L Repetto
- Department of Medical Oncology I, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Bruzzone M, Campora E, Chiara S, Giudici S, Merlini L, Simoni C, Mammoliti S, Rubagotti A, Rosso R. Cerebral metastases secondary to ovarian cancer: still an unusual event. Gynecol Oncol 1993; 49:37-40. [PMID: 8482558 DOI: 10.1006/gyno.1993.1082] [Citation(s) in RCA: 41] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
An incidence of cerebral metastases secondary to epithelial ovarian cancer as high as 11.6% has been reported in small series and related to the prolonged survival of ovarian cancer patients treated with platinum compounds (Hardy, J. R., and Harvey, V. J. Gynecol. Oncol. 33, 296-300, 1989). A review of the histories of 413 ovarian cancer patients, treated from 1981 to 1989 with platinum-based combination chemotherapy according to the protocols of the Gruppo Oncologico Nord Ovest (GONO) (North West Oncology Group), showed that only 9 patients (2.2%) developed clinical evidence of cerebral metastases. Six of 9 patients had FIGO Stage IIIc disease and 1 each with FIGO Stages Ic, IIc, and IV. All these patients had received cisplatin or carboplatin-based combination chemotherapy. Clinical response to initial cytotoxic therapy was as follows: complete response, 3 patients; partial response, 4 patients; stable disease, 1 patient; progressive disease, 1 patient. Cerebral metastases occurred at a median of 19 months (range 3-36) from diagnosis and median survival of patients with central nervous system (CNS) metastasis was 26 months (range 10-81) from diagnosis of primary disease and 8 months (range 1-45) from diagnosis of CNS involvement. The incidence of CNS metastases in our series is similar to that reported in the past and significantly lower than figures reported by the above mentioned paper. On the basis of our data we do not agree with Hardy and Harvey about the relationship possibly existing between prolonged survival and incidence of CNS metastases and, particularly, about the need for prophylactic cranial irradiation.
Collapse
Affiliation(s)
- M Bruzzone
- Instituto Nazionale per la Ricerca sul Cancro-Genoa, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Abstract
One hundred and thirty-seven breast cancer patients, 102 receiving adjuvant chemotherapy and 35 receiving palliative chemotherapy for metastatic disease underwent a 37-item quality-of-life questionnaire to evaluate the impact of disease and treatment on physical, psychological and social well being. Patient groups were designated as follows--Adj CT: patients undergoing the questionnaire during their adjuvant chemotherapy program; Post Adj CT: patients evaluated 3 to 8 months after termination of adjuvant chemotherapy; Mts CT: patients assessed during palliative chemotherapy for metastatic disease, and Post Mts CT: patients 3 to 8 months after termination of palliative chemotherapy. Physical and social activities were reported as unaltered or normal by 64 to 70% and 52 to 67% of patients, respectively. Psychological status was judged normal by 39 to 45% of patients. No significant differences were observed between the patients groups. In 83 to 90% of cases the patient normally took care of herself. In 62 to 87% of cases time dedicated to recreational activities was reported as unaltered. The majority of patients (84%) judged that their relationship with partner and/or family were good. Severe anxiety was reported in 19 to 28% of patients and severe depression was infrequent (3.9%). Information regarding disease and treatment given by health professionals was considered satisfactory by 80 to 100% of patients.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- E Campora
- Department of Medical Oncology, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
| | | | | | | | | | | | | |
Collapse
|
36
|
Repetto L, Miglietta L, Gardin G, Naso C, Giudici S, Merlini L, Queirolo P, Campora E, Pronzato P, Rosso R. Mitoxantrone and mitomycin C as second-line treatment for advanced breast cancer. Ann Oncol 1992; 3:165-6. [PMID: 1606088 DOI: 10.1093/oxfordjournals.annonc.a058135] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
Forty-three evaluable patients with advanced breast cancer were treated with a combination of mitoxantrone 10 mg/sqm and mitomycin C 10 mg/sqm every 3 weeks. Two patients (4%) achieved objective responses lasting 3 and 16 months. The median duration of survival after protocol entry was 6 months (range 1-22) and the median progression-free survival was 3.5 (range 1-20). Only mild toxicities were observed. We concluded that the mitoxantrone and mitomycin C combination has limited toxicity but low activity and only brief disease palliation in advanced breast cancer.
Collapse
Affiliation(s)
- L Repetto
- Divisione di Oncologia Medica, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Miglietta L, Repetto L, Gardin G, Amoroso D, Giudici S, Naso C, Merlini L, Queirolo P, Campora E, Pronzato P. Tamoxifen and alpha interferon in advanced breast cancer. J Chemother 1991; 3:383-6. [PMID: 1819622 DOI: 10.1080/1120009x.1991.11739125] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Thirteen pretreated advanced breast cancer patients received a combination of alpha interferon 5 million IU every 2 days, subcutaneously, plus tamoxifen 10 mg 3 times daily, until disease progression. The objective response rate was 15.4%: 1 patient achieved a complete response, 1 a partial response and 11 demonstrated stable disease; half of the patients were receptor negative and/or pretreated with hormonotherapy. Durations of response were 16 and 26 months for the CR and PR patients respectively; median progression-free survival was 4 months (range 0-26). Toxicities were registered according to WHO criteria: 4 patients stopped the treatment with interferon because of severe flu-like symptoms, while in the others the combination was generally accepted with good tolerance.
Collapse
Affiliation(s)
- L Miglietta
- Istituto Nazionale per la Ricerca sul Cancro, Dept. of Medical Oncology, Genova, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Bruzzone M, Campora E, Merlini L, Giudici S, Bottero G, Iskra L, Donadio M, Ferrari I, Ragni N. Ifosfamide and etoposide salvage treatment in advanced ovarian cancer. J Chemother 1991; 3:332-4. [PMID: 1809812 DOI: 10.1080/1120009x.1991.11739115] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Twelve FIGO stage III-IV ovarian cancer patients progressing or relapsing after primary cisplatin-containing combination chemotherapy were treated with ifosfamide and etoposide. Only patients with clinically evaluable disease entered the trial. The 12 patients received a median number of 3 courses (range 1-6). No complete or partial response and two disease stabilizations were observed. Ten patients progressed on therapy. The combination of ifosfamide and etoposide does not appear to be an effective salvage treatment for advanced ovarian cancer.
Collapse
Affiliation(s)
- M Bruzzone
- Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Jenkins DJ, Wolever TM, Buckley G, Lam KY, Giudici S, Kalmusky J, Jenkins AL, Patten RL, Bird J, Wong GS. Low-glycemic-index starchy foods in the diabetic diet. Am J Clin Nutr 1988; 48:248-54. [PMID: 3407604 DOI: 10.1093/ajcn/48.2.248] [Citation(s) in RCA: 147] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
Abstract
Eight patients with noninsulin-dependent diabetes underwent two 2-wk study periods in random order during which they were provided with carbohydrate foods with either a high or low glycemic index (GI). Over both high-GI and low-GI periods there were significant reductions in body weight, serum fructosamine, and cholesterol. Reductions in fasting blood glucose, HbA1c, and urinary c-peptide-to-creatinine ratio were significant only over the low-GI period despite a smaller mean weight loss. Reductions in triglyceride were significant only over the high-GI diet. Inclusion of low-GI foods into diets of patients with diabetes may be an additional measure that favorably influences carbohydrate metabolism without increasing insulin demand.
Collapse
Affiliation(s)
- D J Jenkins
- Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, Canada
| | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Bravaccio F, Guizzaro A, Giudici S, Paolozzi C. [Variability and specificity of EEG reports in Creutzfeldt-Jakob disease]. Acta Neurol (Napoli) 1986; 8:375-81. [PMID: 3535418] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
|
41
|
Guizzaro A, Tata MR, Volpe E, Giudici S, Mignini R, Bravaccio F. [Further considerations on epilepsy in the follow-up of patients subjected to surgery for intracranial pathology]. Riv Neurol 1986; 56:259-70. [PMID: 3563314] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
A retrospective study has been carried out on a pool of 210 pts. suffering from various intracranial lesions (tumours, abscesses, vascular malformations, hydrocephalus), submitted to neurosurgical operation. The main evidences of our investigation are: both early and tardive seizures are observed only related to supratentorial pathology, mainly to tumours; pts. with seizures before the operation present a major incidence of postoperative epilepsy; and pts. with early seizures have more often also late epilepsy. The Authors relate this evidence to a factor of individual predisposition; pharmacological prophylaxis can be really effective in reducing postoperative epilepsy.
Collapse
|
42
|
Wolever TM, Jenkins DJ, Kalmusky J, Giordano C, Giudici S, Jenkins AL, Thompson LU, Wong GS, Josse RG. Glycemic response to pasta: effect of surface area, degree of cooking, and protein enrichment. Diabetes Care 1986; 9:401-4. [PMID: 3743316 DOI: 10.2337/diacare.9.4.401] [Citation(s) in RCA: 66] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
To see whether food form, the degree of cooking, or protein enrichment affected the glycemic response to pasta, we gave test-meal breakfasts to 13 diabetic patients. Macaroni had a significantly greater glycemic index (GI) (68 +/- 8) than spaghetti (45 +/- 6, P less than .01); the GI of star pastina was intermediate (54 +/- 6). The GI of spaghetti was not significantly affected by cooking for 5 or 15 min (45 +/- 6 and 46 +/- 5, respectively), or by protein enrichment (38 +/- 4). The GI of spaghetti was similar in 11 non-insulin-dependent and 6 insulin-dependent diabetic patients (49 +/- 7 compared with 57 +/- 8). We conclude that different types of pasta may produce different glycemic responses but that these are not necessarily related to differences in cooking or surface area.
Collapse
|
43
|
Jenkins DJ, Wolever TM, Jenkins AL, Giordano C, Giudici S, Thompson LU, Kalmusky J, Josse RG, Wong GS. Low glycemic response to traditionally processed wheat and rye products: bulgur and pumpernickel bread. Am J Clin Nutr 1986; 43:516-20. [PMID: 3962904 DOI: 10.1093/ajcn/43.4.516] [Citation(s) in RCA: 106] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Abstract
To look at the effect of processing wheat and rye on blood glucose responses with special reference to bulgur and pumpernickel bread, groups of 9-12 Noninsulin-dependent (NIDDM) and 5-6 Insulin-dependent diabetic volunteers (IDDM) were fed test meals containing 50 g carbohydrate portions of four wheat and three rye products. Glycemic indices for IDDM and NIDDM combined, calculated as the incremental area under the blood glucose response curve, where white bread = 100, demonstrated values of 96 +/- 5 for wholemeal wheat bread, 89 +/- 6 for wholemeal rye bread, 78 +/- 3 for pumpernickel bread, 65 +/- 4 for bulgur, 63 +/- 6 for whole wheat kernels and 48 +/- 5 for whole rye kernels. Results for IDDM and NIDDM were similar (r = 0.96, p less than 0.01). It is concluded that traditional processing of cereals, such as parboiling (bulgur) or the use of wholegrains in bread (pumpernickel) may result in the low GI value associated with the unmilled cereal. Cereal foods processed in these ways may form a useful part of the diet where a reduction in postprandial glycemia is required.
Collapse
|
44
|
Jenkins DJ, Wolever TM, Kalmusky J, Giudici S, Giordano C, Wong GS, Bird JN, Patten R, Hall M, Buckley G. Low glycemic index carbohydrate foods in the management of hyperlipidemia. Am J Clin Nutr 1985; 42:604-17. [PMID: 2996324 DOI: 10.1093/ajcn/42.4.604] [Citation(s) in RCA: 128] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023] Open
Abstract
Reduction in the mean glycemic index (GI) of diets of 12 hyperlipidemic patients from 82 +/- 1 to 69 +/- 2 units (p less than 0.001) for a 1 mo period resulted in a significant reduction in total and LDL serum cholesterol and serum triglyceride by comparison with the mean lipid values for the preceding and following control months. The change in GI of the diet was achieved largely through manipulation of the cereal products and was not related to large differences in the amount of dietary fiber. In addition, apart from a small mean increase in unsaturated fat and calorie intake during the control periods, no difference was seen between the proportion of macronutrients on either treatment as determined by 1 wk diet histories recorded on alternate weeks throughout the 3 mo study. Selection of low glycemic index foods may therefore be a useful adjunct to the management of hyperlipidemia.
Collapse
|
45
|
Aloj Totàro E, Russo P, Fucci A, Crisci A, Ferraro R, Giudici S. [The electrical discharge of Torpedo marmorata under normal conditions and during hypoxia and anoxia. I]. Boll Soc Ital Biol Sper 1984; 60:2281-4. [PMID: 6529504] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
The electric discharge of Torpedo M. can be considered as an index of the metabolic activity of the electric lobe of C.N.S. In groups of 10 Torpedoes the electric charge was measured: the mechanical stimulus was obtained by the falling of different weights from a determinate height. The experiment was then repeated in conditions of hypoxia: a fall of the electric discharge values was observed. The experiment was also carried out considering the time: after 14 hours the condition of anoxia occurred.
Collapse
|